# OMTX705

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/omtx705
Canonical HTML page: https://getbiobrief.com/entity/omtx705

## Recent coverage (1 stories)

### HanchorBio Broadens HCB101 via InxMed Pact, Testing 2 Agents Beyond Gastric Cancer
2026-07-12 02:54:18 · Sentiment: Positive · Impact: 7/10 · Sources: 3

In a preclinical MOU, HanchorBio will evaluate its CD47/SIRPα asset HCB101 alongside InxMed’s ifebemtinib and OMTX705. The partnership signals a strategic pivot toward using HCB101 as a combination backbone, potentially de-risking the single-indication pipeline and differentiating the asset in a tricky class.
Full story: https://getbiobrief.com/story/hanchorbio-inxmed-hcb101-broadens-indication

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.